GlassScriptPhysician profile
Charles B Kim
NPI 1710912829
$8,745.27
in general payments reported to CMS, 2019-2025
27 companies · $865 in 2025
The $865 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,654 · 2020: $960 · 2021: $1,251 · 2022: $619 · 2023: $313 · 2024: $1,083 · 2025: $865.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,261.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,261.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,870.06 | 2021-2025 | Onyx Frontier, Endurant Iis, Symplicity G3 |
| Abiomed | $1,601.23 | 2019-2025 | Impella |
| Penumbra, INC. | $1,032.84 | 2019 | |
| Abbott Laboratories | $898.26 | 2019-2022 | |
| Amgen INC. | $460.53 | 2019-2025 | Repatha, Repatha |
| Medtronic Vascular, INC. | $394.73 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $326.77 | 2019-2025 | Camzyos, Eliquis |
| Astrazeneca Pharmaceuticals LP | $322.29 | 2019-2025 | Farxiga |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $320.47 | 2019-2024 | Lifevest |
| Janssen Pharmaceuticals, INC | $270.81 | 2019-2022 | |
| Philips North America LLC | $258.06 | 2019 | |
| Novartis Pharmaceuticals Corporation | $226.26 | 2019-2025 | |
| Cardiovascular Systems INC. | $175.26 | 2019-2021 | |
| Inspire Medical Systems, INC. | $89.30 | 2023-2025 | Inspire |
| Merz North America, INC. | $89.19 | 2019 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $76.19 | 2019-2024 | |
| W. L. Gore & Associates, INC. | $60.47 | 2019 | |
| Boston Scientific Corporation | $53.34 | 2020-2021 | |
| Novo Nordisk INC | $43.07 | 2025 | Wegovy |
| Chiesi USA, INC. | $41.14 | 2019-2024 | Kengreal, Cleviprex |
| Boehringer Ingelheim Pharmaceuticals, INC. | $27.98 | 2019 | |
| Biosense Webster, INC. | $25.95 | 2019-2021 | |
| Baxter Healthcare | $18.68 | 2025 | Perclot |
| Sanofi-Aventis U.S. LLC | $18.22 | 2019 | |
| Merck Sharp & Dohme LLC | $17.45 | 2025 | Verquvo |
| Bayer Healthcare Pharmaceuticals INC. | $15.52 | 2025 | |
| Amarin Pharma, INC. | $11.20 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Kim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.